SCHEMBL4807256

SCHEMBL4807256

O=C(NO)c1ncc2c(ccn2Cc2ccc(F)cc2)c1CCCO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.44
HDAC6 Q9UBN7 9/20 0.44
HDAC2 Q92769 6/20 0.44
HDAC8 Q9BY41 5/20 0.44
HDAC3 O15379 5/20 0.44
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
MAOB P27338 1/20 0.42
HDAC10 Q969S8 4/20 0.38
HDAC9 Q9UKV0 3/20 0.38
CNR2 P34972 2/20 0.38
CNR1 P21554 1/20 0.38
RAB9A P51151 1/20 0.37
HTR6 P50406 1/20 0.37
HDAC7 Q8WUI4 3/20 0.36
HDAC4 P56524 3/20 0.36
MMP13 P45452 1/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
NCOR2 Q9Y618 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496597 0.89 CYP11B1 (0.46) CYP11B1CYP11B2MAOBCNR2RAB9A
SCHEMBL4801391 0.86 HDAC6 (0.46) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL3496747 0.84 CYP11B1 (0.42) CYP11B1CYP11B2MAOBRAB9A
SCHEMBL14533493 0.84 HDAC6 (0.47) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL4803201 0.83 HDAC3 (0.48) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL3495643 0.82 EGLN1 (0.43) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL3494864 0.80 CNR2 (0.35) CYP11B1CYP11B2MAOBCNR2CNR1
SCHEMBL4965274 0.79 HSP90AA1 (0.42) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL4801027 0.79 HDAC1 (0.45) HDAC1HDAC6HDAC2HDAC8HDAC3
SCHEMBL14541609 0.79 POLB (0.41) CYP11B1CYP11B2MAOBCNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468375-B2 Inhibitors of the HIV integrase enzyme PFIZER INC. (US) 2008-12-23 US claimed
EP-1756103-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS Pfizer, Inc. (US) 2007-02-28 EP claimed
US-20050277662-A1 Inhibitors of the HIV integrase enzyme AGOURON PHARMACEUTICALS, INC 2005-12-15 US claimed
WO-2005103003-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS PFIZER INC. (US) 2005-11-03 WO claimed
US-7468375-B2 Inhibitors of the HIV integrase enzyme PFIZER INC. (US) 2008-12-23 US disclosed
US-7468375-B2 Inhibitors of the HIV integrase enzyme PFIZER INC. (US) 2008-12-23 US disclosed
US-7468375-B2 Inhibitors of the HIV integrase enzyme PFIZER INC. (US) 2008-12-23 US disclosed
EP-1756103-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS Pfizer, Inc. (US) 2007-02-28 EP disclosed
US-20050277662-A1 Inhibitors of the HIV integrase enzyme AGOURON PHARMACEUTICALS, INC 2005-12-15 US disclosed
WO-2005103003-A2 PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS PFIZER INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277662-A1 Inhibitors of the HIV integrase enzyme IMPDH1, INTS9, TYMP HDAC1 626/4885HDAC6 1926/4885HDAC2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.